Chronic phospholamban-sarcoplasmic reticulum calcium atpase interaction is the critical calcium cycling defect in dilated cardiomyopathy

Cell

Volumn 99, Issue 3, 1999, Pages 313-322

  Minamisawa, Susumu ^a,b   Hoshijima, Masahiko ^a,b   Chu, Guoxiang ^d   Ward, Christopher A ^e,g   Frank, Konrad ^d   Gu, Yusu ^b   Martone, Maryann E ^c   Wang, Yibin ^a,b,f   Ross Jr , John ^a,b   Kranias, Evangelia G ^d   Giles, Wayne R ^e   Chien, Kenneth R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Molecular Genetics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); PHOSPHOLAMBAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; GENE; HEART DILATATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SARCOPLASMIC RETICULUM;

ANIMALIA;

EID: 0033615645     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81662-1     Document Type: Article

References (52)

1. Arber, S., Hunter, J.J., Ross, J., Jr., Hongo, M., Sansig, G., Borg, J., Perriard, J.C., Chien, K.R., and Caroni, P. (1997). MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393-403.
2. Badorff, C., Lee, G.H., Lamphear, B.J., Maitone, M.E., Campbell, K.P., Rhoads, R.E., and Knowlton, K.U. (1999). Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5, 320-326.
3. Balke, C.W., and Shorofsky, S.R. (1998). Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc. Res. 37, 290-299.
4. Bristow, M.R., Ginsburg, R., Minobe, W., Cubicciotti, R.S., Sageman, W.S., Lurie, K., Billingham, M.E., Harrison, D.C., and Stinson, E.B. (1982). Decreased catecholamine sensitivity and beta-adrenergicreceptor density in failing human hearts. N. Engl. J. Med. 307, 205-211.
5. Chen, J., and Chien, K.R. (1999). Complexity in simplicity: monogenie disorders and complex cardiomyopathies. J. Clin. Invest. 103, 1483-1485.
6. Chien, K.R. (1999). Stress pathways and heart failure. Cell 98, 555-558.
7. Chien, K.R., Zhu, H., Knowlton, K.U., Miller-Hance, W., van-Bilsen, M., O'Brien, T.X., and Evans, S.M. (1993). Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 55, 77-95.
8. Chien, K.R., Grace, A.A., and Hunter, J.J. (1999). Molecular and cellular biology of cardiac hypertrophy and failure. In Molecular Basis of Cardiovascular Disease. K. Chien, ed. (Cambridge, MA: W.B. Saunders Co.), pp. 211-250.
9. Christensen, G., Minamisawa, S., Gruber, P., Wang, Y., and Chien, K.R. (1999). High efficiency long term cardiac expression of foreign genes in living mouse embryos and neonates. Circulation, in press.
10. Chu, G., Luo, W., Slack, J.P., Tilgmann, C., Sweet, W.E., Spindler, M., Saupe, K.W., Boivin, G.P., Moravec, C.S., Matlib, M.A., et al. (1996). Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79, 1064-1076.
11. Coral-Vazquez, R., Cohn, R.D., Moore, S.A., Hill, J.A., Weiss, R.M., Davisson, R.L., Straub, V., Barresi, R., Bansal, D., Hrstka, R.F., et al. (1999). Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98, 465-474.
12. Feldman, A.M., Gates, A.E., Veazey, W.B., Hershberger, R.E., Bristow, M.R., Baughman, K.L., Baumgartner, W.A., and Van Dop, C. (1988). Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J. Clin. Invest. 82, 189-197.
13. Gomez, A.M., Valdivia, H.H., Cheng, H., Lederer, M.R., Santana, L.F., Cannell, M.B., McCune, S.A., Altschuld, R.A., and Lederer, W.J. (1997). Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276, 800-806.
14. Gruver, C.L., DeMayo, F., Goldstein, M.A., and Means, A.R. (1993). Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology 133, 376-388.
15. Hasenfuss, G. (1998). Alterations of calcium-regulatory proteins in heart failure. Cardiovasc. Res. 37, 279-289.
16. Hirota, H., Chen, J., Betz, U.A., Rajewsky, K., Gu, Y., Ross, J., Jr., Muller, W., and Chien, K.R. (1999). Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189-198.
17. Hunter, J.J., and Chien, K.R. (1999). Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341, 1276-1283.
18. Jones, W.K., Grupp, I.L., Doetschman, T., Grupp, G., Osinska, H., Hewett, T.E., Boivin, G., Gulick, J., Ng, W.A., and Robbins, J. (1996). Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J. Clin. Invest. 98, 1906-1917.
19. Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D.H. (1997). Phospholamban inhibitory function is activated by depolymerization. J. Biol. Chem. 272, 15061-15064.
20. 2+ -ATPase isoform of cardiac sarcoplasmic reticulum. J. Biol. Chem. 273, 14238-14241.
21. Koch, W.J., Rockman, H.A., Samama, P., Hamilton, R.A., Bond, R.A., Milano, C.A., and Lefkowitz, R.J. (1995). Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268, 1350-1353.
22. Koss, K.L., and Kranias, E.G. (1996). Phospholamban: a prominent regulator of myocardial contractility. Circ. Res. 79, 1059-1063.
23. Koss, K.L., Grupp, I.L., and Kranias, E.G. (1997). The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res. Cardiol. 92, 17-24.
24. Lindner, M., Erdmann, E., and Beuckelmann, D.J. (1998). Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. J. Mol. Cell. Cardiol. 30, 743-749.
25. Luo, W., Grupp, I.L., Harrer, J., Ponniah, S., Grupp, G., Duffy, J.J., Doetschman, T., and Kranias, E.G. (1994). Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75, 401-409.
26. Luo, W., Chu, G., Sato, Y., Zhou, Z., Kadambi, V.J., and Kranias, E.G. (1998). Transgenic approaches to define the functional role of dual site phospholamban phosphorylation. J. Biol. Chem. 273, 4734-4739.
27. Marione, M.E., Jones, Y.Z., Young, S.J., Ellisman, M.H., Zivin, J.A., and Hu, B.R. (1999). Modification of postsynaptic densities after transient cerebral ischemia: a quantitative and three-dimensional ultrastructural study. J. Neurosci. 19, 1988-1997.
28. McDonough, P.M., Hanford, D.S., Sprenkle, A.B., Mellon, N.R., and Glembotski, C.C. (1997). Collaborative roles for c-Jun N-terminal kinase, c-Jun, serum response factor, and Sp1 in calcium-regulated myocardial gene expression. J. Biol. Chem. 272, 24046-24053.
29. 2+ . Biochem. J. 269, 513-519.
30. Meyer, M., Schillinger, W., Pieske, B., Holubarsch, C., Heilmann, C., Posival, H., Kuwajima, G., Mikoshiba, K., Just, H., Hasenfuss, G., et al. (1995). Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778-784.
31. Minamisawa, S., Gu, Y., Ross, J., Jr., Chien, K.R., and Chen, J. (1999). A post-transcriptional compensatory pathway in heterozygous ventricular myosin light chain 2-deficient mice results in lack of gene dosage effect during normal cardiac growth or hypertrophy. J. Biol. Chem. 274, 10066-10070.
32. Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R., and Olson, E.N. (1998). A calcineui independent tiansciiptional pathway for cardiac hypertrophy. Cell 93, 215-228.
33. Morgan, J.P. (1991). Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N. Engl. J. Med. 325, 625-632.
34. Olson, T.M., Michels, V.V., Thibodeau, S.N., Tai, Y.S., and Keating, M.T. (1998). Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280, 750-752.
35. Palakodeti, V., Oh, S., Oh, B.H., Mao, L., Hongo, M., Peterson, K.L., and Ross, J., Jr. (1997). Force-frequency effect is a powerful determinant of myocardial contractility in the mouse. Am. J. Physiol. 273, H1283-H1290.
36. Pieske, B., Kretschmann, B., Meyer, M., Holubarsch, C., Weirich, J., Posival, H., Minami, K., Just, H., and Hasenfuss, G. (1995). Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. 92, 1169-1178.
37. Qi, M., Shannon, T.R., Euler, D.E., Bers, D.M., and Samarel, A.M. (1997). Downregulation of sarcoplasmic reticulum Ca(2+)-ATPase during progression of left ventricular hypertrophy. Am. J. Physiol. 272, H2416-H2424.
38. 2+ /calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J. Biol. Chem. 272, 31203-31208.
39. Rockman, H.A., Chien, K.R., Choi, D.J., laccarino, G., Hunter, J.J., Ross, J., Jr., Lefkowitz, R.J., and Koch, W.J. (1998). Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. USA 95, 7000-7005.
40. + channels in slip-mode conductance. J. Gen. Physiol. 772, 11a-12a.
41. Sato, Y., Ferguson, D.G., Sako, H., Dorn, G.W. II, Kadambi, V.J. , Yatani, A., Hoit, B.D., Walsh, R.A., and Kranias, E.G. (1998). Cardiacspecific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J. Biol. Chem. 273, 28470-28477.
42. Schmidt, U., Hajjar, R.J., Kim, C.S., Lebeche, D., Doye, A.A., and Gwathmey, U.K. (1999). Human heart failure: cAMP stimulation of SR Ca(2 + )-ATPase activity and phosphorylation level of phospholamban. Am. J. Physiol. 277, H474-H480.
43. Schwinger, R.H., Munch, G., Bolck, B., Karczewski, P., Krause, E.G., and Erdmann, E. (1999). Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serine-16 phospholamban phosphorylation. J. Mol. Cell. Cardiol. 31, 479-491.
44. Simmerman, H.K., and Jones, L.R. (1998). Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78, 921-947.
45. Sordahl, LA., McCollum, W.B., Wood, W.G., and Schwartz, A. (1973). Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. Am. J. Physiol. 224, 497-502.
46. Tada, M., and Toyofuku, T. (1998). Molecular regulation of phospholamban function and expression. Trends Cardiovasc. Med. 8, 330-340.
47. Tada, M., Yamada, M., Kadoma, M., Inui, M., and Ohmori, F. (1982). Calcium transport by cardiac sarcoplasmic reticulum and phosphorylation of phospholamban. Mol. Cell. Biochem. 46, 73-95.
48. Tanaka, N., Dalton, N., Mao, L., Rockman, H.A., Peterson, K.L., Gottshall, K.R., Hunter, J.J., Chien, K.R., and Ross, J., Jr. (1996). Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 94, 1109-1117.
49. Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D.H. (1994). Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca(2+)-ATPase of sarcoplasmic reticulum. J. Biol. Chem. 269,3088-3094.
50. Wang, Y., Huang, S., Sah, V.P., Ross, J., Jr., Brown, J.H., Han, J., and Chien, K.R. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273, 2161-2168.
51. Ward, C.A., and Giles, W.R. (1997). Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J. Physiol. (Lond.) 500, 631-642.
52. Whitmer, J.T., Kumar, P., and Solaro, R.J. (1988). Calcium transport properties of cardiac sarcoplasmic reticulum from cardiomyopathic Syrian hamsters (BIO 53.58 and 14.6): evidence for a quantitative defect in dilated myopathic hearts not evident in hypertrophie hearts. Circ. Res. 62, 81-85.